keyword
MENU ▼
Read by QxMD icon Read
search

oral oncology

keyword
https://www.readbyqxmd.com/read/29661495/narcotics-reduction-quality-and-safety-in-gynecologic-oncology-surgery-in-the-first-year-of-enhanced-recovery-after-surgery-protocol-implementation
#1
Jennifer E Bergstrom, Marla E Scott, Yewande Alimi, Ting-Tai Yen, Deborah Hobson, Karime K Machado, Edward J Tanner, Amanda N Fader, Sarah M Temkin, Stephanie Wethington, Kimberly Levinson, Sam Sokolinsky, Brandyn Lau, Rebecca L Stone
OBJECTIVES: Enhanced Recovery After Surgery (ERAS) programs are mechanisms for achieving value-based improvements in surgery. This report provides a detailed analysis of the impact of an ERAS program on patient outcomes as well as quality and safety measures during implementation on a gynecologic oncology service at a major academic medical center. METHODS: A retrospective review of gynecologic oncology patients undergoing elective laparotomy during the implementation phase of an ERAS program (January 2016 through December 2016) was performed...
April 13, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29660835/pdgfra-mrna-overexpression-is-associated-with-regional-metastasis-and-reduced-survival-in-oral-squamous-cell-carcinoma
#2
Hui Shan Ong, Sandhya Gokavarapu, Zhen Tian, Jiang Li, Qin Xu, Chen Ping Zhang, Wei Cao
BACKGROUND: Platelet-derived growth factor alpha (PDGFRA) is a gene encoding tyrosine kinase receptor and both EGFR and PDGFRA activate tyrosine kinase. The implication of PGFRA in many cancers and its prognostic significance irrespective to EGFR status in spinal chordoma, gliomas and uterine cancers has shown a need for its investigation in oral squamous cell carcinoma (OSCC). We investigated the prognostic value of PDGFRA mRNA expression in OSCC. PATIENTS AND METHODS: The study was conducted in the department of oral maxillofacial surgery-head and neck oncology, at a tertiary hospital...
April 16, 2018: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/29651970/randomized-double-blind-placebo-controlled-trial-of-celecoxib-for-prevention-of-skin-toxicity-in-patients-receiving-radiation-therapy-for-breast-cancer
#3
Arash Ghasemi, Behzad Danesh, Jamshid Yazdani, Seyed Jalal Hosseinimehr
BACKGROUND: The skin toxicity-induced by ionizing radiation may limit the duration of treatment and may lead discomfort to quality life of patients during radiotherapy. OBJECTIVE: The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of oral administration of celecoxib (CLX) on the acute radiation-induced skin toxicity in patients with breast cancer. METHODS: Sixty breast cancer patients were randomly assigned to use CLX (400 mg per day) or placebo capsules during radiotherapy...
April 11, 2018: Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29650946/a-rare-case-of-relapsed-pediatric-acute-promyelocytic-leukemia-with-skin-involvement-by-myeloid-sarcoma
#4
Nathalia Silva Araújo, Claudio José Dos Santos Júnior, Vitória Mikaelly da Silva Gomes, Luiz Arthur Calheiros Leite, Luana Novaes Bomfim, Amanda Katielly Firmino da Silva Gusmão, Maria Jordana Rocha Gomes Alves, Cyndi Myrelle da Silva Barros Romão, Arthur Moacir Costa Sampaio Batinga, Maria Rosa da Silva, Célio Fernando de Sousa Rodrigues
BACKGROUND Acute promyelocytic leukemia (APL) is a very rare leukemia in children. Extramedullary involvement by APL has been reported in between 3-5% of cases, mainly associated with cases of relapse. A rare case of relapse of APL in a 9-year-old child is presented with skin involvement with myeloid sarcoma. CASE REPORT A 9-year-old male child was admitted to the Oncology Service of the hospital complaining of fever, progressive fatigue, oral petechiae with severe bleeding in the oral cavity. Bone marrow examination showed some promyelocytes...
April 13, 2018: American Journal of Case Reports
https://www.readbyqxmd.com/read/29650686/use-of-direct-oral-anticoagulants-in-patients-with-cancer-practical-considerations-for-the-management-of-patients-with-nausea-or-vomiting
#5
REVIEW
Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer-Westendorf, Francis Cajfinger, Ian Chau, Alexander T Cohen, Alok A Khorana, Anthony Maraveyas, Marcos Renni, Annie M Young
Direct oral anticoagulants (DOACs) have proven efficacy and safety and are approved for use in the prevention and treatment of thromboembolic events in patients with venous thromboembolism (VTE) and those with atrial fibrillation (AF). There is no clear guidance on the use of DOACs in the significant proportion of these patients who have or will develop concomitant cancer. The occurrence of nausea and vomiting in these patients, despite implementation of guideline-recommended antiemetic strategies, is a particular concern because it may affect oral drug intake and consequently outcomes with anticoagulation therapy...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29650362/tazemetostat-an-ezh2-inhibitor-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-and-advanced-solid-tumours-a-first-in-human-open-label-phase-1-study
#6
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, Jean-Marie Michot, Carlo Lucchesi, Andrea Varga, Jean-Michel Coindre, Stephen J Blakemore, Alicia Clawson, Benjamin Suttle, Alice A McDonald, Mark Woodruff, Scott Ribich, Eric Hedrick, Heike Keilhack, Blythe Thomson, Takashi Owa, Robert A Copeland, Peter T C Ho, Vincent Ribrag
BACKGROUND: Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the subunits INI1 or SMARCA4) can lead to aberrant histone methylation, oncogenic transformation, and a proliferative dependency on EZH2 activity. In this first-in-human study, we aimed to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of tazemetostat, a first-in-class selective inhibitor of EZH2...
April 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29628465/-pharmacological-characteristics-and-clinical-study-results-of-the-oral-proteasome-inhibitor-ixazomib-ninlaro-%C3%A2-capsules-2-3-mg-3-mg-and-4-mg
#7
Michiko Machida, Shinichi Fukunaga, Takahito Hara
Ixazomib (Ninlaro® capsule) is an oral small molecule 20S proteasome inhibitor created by Millennium Pharmaceuticals, Inc (Takeda Oncology Company). Ubiquitin proteasome system is a major regulatory system for maintaining protein homeostasis, and an important mechanism for degrading proteins, such as those involved in proliferation regulation, cell cycle regulation and apoptosis, in cells. Ixazomib selectively and reversibly binds to the β5 subunit of the 20S proteasome, inhibits its chymotrypsin-like activity, and thereby accumulates ubiquitinated proteins...
2018: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/29625879/tivantinib-for-second-line-treatment-of-met-high-advanced-hepatocellular-carcinoma-metiv-hcc-a-final-analysis-of-a-phase-3-randomised-placebo-controlled-study
#8
Lorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, Marc Pracht, Vittorina Zagonel, Philippe Mathurin, Elena Rota Caremoli, Camillo Porta, Bruno Daniele, Luigi Bolondi, Vincenzo Mazzaferro, William Harris, Nevena Damjanov, Davide Pastorelli, María Reig, Jennifer Knox, Francesca Negri, Jörg Trojan, Carlos López López, Nicola Personeni, Thomas Decaens, Marie Dupuy, Wolfgang Sieghart, Giovanni Abbadessa, Brian Schwartz, Maria Lamar, Terri Goldberg, Dale Shuster, Armando Santoro, Jordi Bruix
BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial. METHODS: We did a phase 3, randomised, double-blind, placebo-controlled study in 90 centres in Australia, the Americas, Europe, and New Zealand...
April 3, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29625408/nutritional-intervention-in-head-and-neck-cancer-patients-during-chemo-radiotherapy
#9
Serena Della Valle, Silvia Colatruglio, Vanessa La Vela, Elena Tagliabue, Luigi Mariani, Cecilia Gavazzi
OBJECTIVE: Head and neck cancer patients experience unintentional weight loss and malnutrition at diagnosis, during oncologic treatment, and after the end of therapy because of reduction of eating ability. The aim of the present study was to assess nutrition intervention efficacy in maintaining basal nutritional conditions. METHODS: Head and neck cancer patient candidates for chemoradiotherapy and requiring enteral nutrition (EN) support through gastrostomy, according to international guidelines, were included in the study...
February 5, 2018: Nutrition
https://www.readbyqxmd.com/read/29620791/feasibility-of-all-oral-anti-hcv-treatment-during-dhap-chemotherapy-and-autologous-stem-cell-transplantation-for-t-cell-lymphoma
#10
Roberto Rossotti, Chiara Rusconi, Chiara Baiguera, Vittorio Ruggero Zilioli, Giovanni Grillo, Marco Merli, Emanuele Ravano, Massimo Puoti
The role of anti-HCV direct-acting agents (DAAs) is well described in HCV-related lymphoproliferative disorders, whereas few data are available on their use in other malignancies, such as aggressive T-cell lymphomas requiring autologous stem cell transplantation (ASCT). We describe two oncologic cirrhotic patients treated with DAAs who underwent ASCT achieving cure for both diseases. Co-administration of sofosbuvir with cisplatin led an unexpected severe kidney impairment that did not resolve 30 weeks after drug exposure...
April 5, 2018: New Microbiologica
https://www.readbyqxmd.com/read/29618488/steroid-sulfatase-inhibition-by-aryl-sulfamates-clinical-progress-mechanism-and-future-prospects
#11
Barry V L Potter
Steroid sulfatase is an emerging drug target for the endocrine therapy of hormone-dependent diseases, catalyzing estrogen sulfate hydrolysis to estrogen. Drug discovery, developing the core aryl O-sulfamate pharmacophore, has led to steroidal and non-steroidal drugs entering numerous clinical trials, with promising results in oncology and women's health. Steroidal estrogen sulfamate derivatives were the first irreversible active-site-directed inhibitors and one was developed clinically as an oral estradiol pro-drug and for endometriosis applications...
April 4, 2018: Journal of Molecular Endocrinology
https://www.readbyqxmd.com/read/29618054/influence-of-residual-disease-following-surgical-resection-in-newly-diagnosed-glioblastoma-on-clinical-neurocognitive-and-patient-reported-outcomes
#12
William A Hall, Stephanie L Pugh, Jeffrey S Wefel, Terri S Armstrong, Mark R Gilbert, David G Brachman, Maria Werner-Wasik, Merideth M Wendland, Paul D Brown, Samuel T Chao, Kevin S Roof, H Ian Robins, Minesh P Mehta, Walter J Curran, Benjamin Movsas
BACKGROUND: The influence of subtotal resection (STR) on neurocognitive function (NCF), quality of life, and symptom burden in glioblastoma is unknown. If bevacizumab preferentially benefits patients with STR is unknown. OBJECTIVE: To examine these uncertainties. METHODS: NCF and patient reported outcomes (PRO) were prospectively collected in NRG Oncology RTOG 0525 and 0825. Changes in NCF and PRO measures from baseline to prespecified times were examined by Wilcoxon test, and mixed effects longitudinal modeling, to assess differences between patients who received STR vs gross-total resection...
March 30, 2018: Neurosurgery
https://www.readbyqxmd.com/read/29611527/chemotherapy-medication-errors
#13
REVIEW
Saul N Weingart, Lulu Zhang, Megan Sweeney, Michael Hassett
Although chemotherapy is a well established treatment modality, chemotherapy errors represent a potentially serious risk of patient harm. We reviewed published research from 1980 to 2017 to understand the extent and nature of medication errors in cancer chemotherapy, and to identify effective interventions to help prevent mistakes. Chemotherapy errors occur at a rate of about one to four per 1000 orders, affect at least 1-3% of adult and paediatric oncology patients, and occur at all stages of the medication use process...
April 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29610957/organ-preservation-surgery-for-patients-with-t4a-laryngeal-cancer
#14
Caiyun Zhang, Minhui Zhu, Donghui Chen, Shicai Chen, Hongliang Zheng
PURPOSE: Surgical preservation of laryngeal function is very challenging in patients with advanced SCCL, especially those of stage T4a. The purpose of this study was to assess the feasibility of organ preservation surgery for patients with T4a squamous cell carcinoma of the larynx (SCCL). METHODS: We enrolled 32 patients with T4a SCCL and performed organ preservation surgery on them. Surgical details and perioperative morbidity were described, functional and oncologic outcomes were also evaluated...
April 2, 2018: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/29607820/assessment-of-sunitinib-alternative-prescription-schedules-in-metastatic-kidney-cancer-a-study-of-10-cases
#15
Habib Diallo, Hasnae Alaoui Mhamdi, Salma Elouarzazi, Mohamed Fadli, Rhizlane Belbaraka
BACKGROUND: Managing metastatic Renal Cell Carcinoma (mRCC) has been revolutionized during the first decade of the 21st century due to the development of targeted therapies. The sunitinib is an oral multi-targeted receptor Tyrosine Kinase Inhibitor (TKI). It became the first targeted therapy as first-line treatment to improve the survival of patients with metastatic kidney cancer. This treatment consists in the oral intake of 50 mg of sunitinib per day in a 6 -week cycle including 4 weeks of treatment intake (the "on" week) followed by a 2-week break (the off week)...
January 2018: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/29606586/larotrectinib-for-paediatric-solid-tumours-harbouring-ntrk-gene-fusions-phase-1-results-from-a-multicentre-open-label-phase-1-2-study
#16
Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco, Brian B Tuch, Kevin T Ebata, Mark Reynolds, Steven Smith, Scott Cruickshank, Michael C Cox, Alberto S Pappo, Douglas S Hawkins
BACKGROUND: Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients. METHODS: This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy...
March 29, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29603636/publication-rates-of-abstracts-presented-at-the-royal-australian-and-new-zealand-college-of-radiologists-annual-scientific-meetings-any-change-since-2004
#17
Jeremy D Croker, Sean A Bydder
INTRODUCTION: The aim of this study was to determine the publication rate of abstracts presented at annual Royal Australian and New Zealand College of Radiologists (RANZCR) conferences. METHODS: The College's Annual Scientific Meetings (ASMs) from 2010 to 2013 were examined, with the goal of comparing these results to the findings of an earlier identical study that examined RANZCR ASMs from 1996 to 1999. RESULTS: Of the 1152 research abstracts presented, 468 (41%) had been published as full articles...
March 30, 2018: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29594214/sdf-1-cxcr4-expression-in-head-and-neck-cancer-and-outcome-after-postoperative-radiochemotherapy
#18
Chiara De-Colle, David Mönnich, Stefan Welz, Simon Boeke, Bence Sipos, Falko Fend, Paul-Stefan Mauz, Inge Tinhofer, Volker Budach, Jehad Abu Jawad, Martin Stuschke, Panagiotis Balermpas, Claus Rödel, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Christine Bayer, Claus Belka, Steffi Pigorsch, Stephanie E Combs, Fabian Lohaus, Annett Linge, Mechthild Krause, Michael Baumann, Daniel Zips, Apostolos Menegakis
Introduction: Outcome after postoperative radiochemotherapy (RT-CT) for patients with advanced head and neck squamous cell carcinomas (HNSCC) remains unsatisfactory, especially among those with HPV negative tumours. Therefore, new biomarkers are needed to further define subgroups for individualised therapeutic approaches. Preclinical and first clinical observations showed that the chemokine receptor CXCR4 and its ligand SDF-1 (CXCL12) play an important role in tumour cell proliferation, survival, cancer progression, metastasis and treatment resistance...
August 2017: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/29578121/a-retrospective-study-comparing-surgical-and-early-oncological-outcomes-between-intracorporeal-and-extracorporeal-ileal-conduit-after-laparoscopic-radical-cystectomy-from-a-single-center
#19
Ming-Shuai Wang, Qing-Bao He, Fei-Ya Yang, Hao Ping, Nian-Zeng Xing
Background: Robot-assisted/laparoscopic intracorporeal ileal conduit (ICIC) has been reported in many experienced centers. Whether laparoscopic ICIC is superior to extracorporeal ileal conduit (ECIC) and whether laparoscopic ICIC should be promoted is still controversial. The aim of the study was to compare surgical and early oncological outcomes between patients undergoing laparoscopic radical cystectomy (LRC) with ICIC and ECIC. Methods: From January 2011 to June 2016, a total of 45 patients with bladder cancer underwent LRC with ileal conduit at our department, of whom 20 patients underwent LRC with ECIC and 25 patients underwent LRC with ICIC...
April 5, 2018: Chinese Medical Journal
https://www.readbyqxmd.com/read/29575765/combination-therapy-of-apatinib-with-icotinib-for-primary-acquired-icotinib-resistance-in-patients-with-advanced-pulmonary-adenocarcinoma-with-egfr-mutation
#20
Pinghui Xia, Jinlin Cao, Xiayi Lv, Luming Wang, Wang Lv, Jian Hu
Multi-targeted agents represent the next generation of targeted therapies for solid tumors, and patients with acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) may also benefit from their combination with TKI therapy. Third-generation targeted drugs, such as osimertinib, are very expensive, thus a more economical solution is required. The aim of this study was to explore the use of apatinib combined with icotinib therapy for primary acquired resistance to icotinib in three patients with advanced pulmonary adenocarcinoma with EGFR mutations...
March 24, 2018: Thoracic Cancer
keyword
keyword
91223
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"